|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,250,000,000 |
Market
Cap: |
92.45(B) |
Last
Volume: |
29,395,747 |
Avg
Vol: |
11,996,025 |
52
Week Range: |
$40.25 - $66.16 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 6.8 |
Insider 3/6 Months : 7.4 |
|
Guru Rank Number : 97 |
Guru Rank Value : 8.6 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
2,000 |
13,571 |
13,571 |
Total Buy Value |
$0 |
$99,560 |
$672,994 |
$672,994 |
Total People Bought |
0 |
1 |
2 |
2 |
Total Buy Transactions |
0 |
1 |
3 |
3 |
Total Shares Sold |
0 |
0 |
18,718 |
681,397 |
Total Sell Value |
$0 |
$0 |
$1,146,397 |
$49,727,684 |
Total People Sold |
0 |
0 |
2 |
6 |
Total Sell Transactions |
0 |
0 |
2 |
12 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bancroft Charles A |
EVP, Head of Integration |
|
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,075 |
158,045 |
|
- |
|
Bancroft Charles A |
EVP, Head of Integration |
|
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
71,868 |
153,637 |
|
- |
|
Bancroft Charles A |
EVP, Head of Integration |
|
2020-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(397) |
106,408 |
|
- |
|
Bancroft Charles A |
EVP, Head of Integration |
|
2020-03-10 |
4 |
GA |
$0.00 |
$0 |
I/I |
300,000 |
300,000 |
|
- |
|
Bancroft Charles A |
EVP, Head of Integration |
|
2020-03-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
300,000 |
92,309 |
|
- |
|
Eid Joseph |
SVP,Head Glob. Medical Affairs |
|
2020-03-10 |
4 |
D |
$57.93 |
$36,786 |
D/D |
(635) |
6,445 |
|
- |
|
Eid Joseph |
SVP,Head Glob. Medical Affairs |
|
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
212 |
6,864 |
|
- |
|
Eid Joseph |
SVP,Head Glob. Medical Affairs |
|
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,571 |
6,652 |
|
- |
|
Eid Joseph |
SVP,Head Glob. Medical Affairs |
|
2020-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(30) |
5,922 |
|
- |
|
Boerner Christopher S. |
EVP, Chief Commercial Officer |
|
2020-03-10 |
4 |
D |
$57.43 |
$701,756 |
D/D |
(12,167) |
21,033 |
|
- |
|
Boerner Christopher S. |
EVP, Chief Commercial Officer |
|
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,497 |
27,190 |
|
- |
|
Boerner Christopher S. |
EVP, Chief Commercial Officer |
|
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,426 |
26,091 |
|
- |
|
Boerner Christopher S. |
EVP, Chief Commercial Officer |
|
2020-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(109) |
12,811 |
|
- |
|
Von Autenried Paul |
EVP, Chief Information Officer |
|
2020-03-10 |
4 |
D |
$57.93 |
$622,052 |
D/D |
(10,738) |
146,701 |
|
- |
|
Von Autenried Paul |
EVP, Chief Information Officer |
|
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,030 |
153,636 |
|
- |
|
Von Autenried Paul |
EVP, Chief Information Officer |
|
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,806 |
152,400 |
|
- |
|
Von Autenried Paul |
EVP, Chief Information Officer |
|
2020-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(124) |
139,268 |
|
- |
|
Elicker John E |
EVP, Investor Relations |
|
2020-03-04 |
4 |
S |
$61.01 |
$964,263 |
D/D |
(15,805) |
58,666 |
|
6% |
|
Vessey Rupert |
Pres., Research & Early Dev. |
|
2020-03-02 |
4 |
S |
$60.59 |
$5,108,222 |
D/D |
(84,308) |
48,343 |
|
5% |
|
Vessey Rupert |
Pres., Research & Early Dev. |
|
2020-03-02 |
4 |
OE |
$38.41 |
$4,831,452 |
D/D |
93,468 |
132,651 |
|
- |
|
Elkins David V |
EVP, Chief Financial Officer |
|
2020-03-01 |
4 |
D |
$59.06 |
$618,358 |
D/D |
(10,470) |
34,296 |
|
- |
|
Elkins David V |
EVP, Chief Financial Officer |
|
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,579 |
44,766 |
|
- |
|
Vessey Rupert |
Pres., Research & Early Dev. |
|
2020-03-01 |
4 |
D |
$59.06 |
$526,992 |
D/D |
(8,923) |
39,183 |
|
- |
|
Vessey Rupert |
Pres., Research & Early Dev. |
|
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,349 |
48,106 |
|
- |
|
Ahmed Nadim |
President, Hematology |
|
2020-03-01 |
4 |
D |
$59.06 |
$500,415 |
D/D |
(8,473) |
24,555 |
|
- |
|
2225 Records found
|
|
Page 15 of 89 |
|
|